Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors

Bioorg Med Chem Lett. 2013 May 15;23(10):2897-901. doi: 10.1016/j.bmcl.2013.03.062. Epub 2013 Mar 26.

Abstract

This Letter reports our efforts towards the optimization of our previously identified series of imidazole and triazole derivatives that lead to the discovery of a series of orally active Lp-PLA2 inhibitors in C57 mice. These inhibitors are characterized by the presence of a diamine side chain in the molecules, such as 2c, 2f, and 4a. The introduction of the terminal-end amine succeeded in maintaining the in vitro activities at sub-nanomolar levels. The vivo activities could be greatly affected by variations in the two amines via modulating the metabolic stability and lipophilicity of the compounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / antagonists & inhibitors*
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / blood
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / metabolism
  • Administration, Oral
  • Animals
  • Benzaldehydes / administration & dosage
  • Benzaldehydes / chemistry
  • Benzaldehydes / pharmacology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Molecular Structure
  • Oximes / administration & dosage
  • Oximes / chemistry
  • Oximes / pharmacology*
  • Rabbits
  • Recombinant Proteins / antagonists & inhibitors
  • Recombinant Proteins / metabolism
  • Structure-Activity Relationship

Substances

  • Benzaldehydes
  • Enzyme Inhibitors
  • Oximes
  • Recombinant Proteins
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase
  • darapladib